Druckenmiller: Selling Nvidia and Palantir Was a 'Huge Mistake' — But Healthcare-AI Pivot Continues

In this interview with Iliana Bouzali at Morgan Stanley, Druckenmiller makes a rare public self-critique while simultaneously unveiling his new big bet.

Admission of the Nvidia Mistake "I sold between $800-950, then it went to $1,300. That was a big mistake." Druckenmiller defended this exit with two justifications: valuation and tripling within a single year. But the market proved him wrong. This admission reminds us that even the most experienced investors can make timing errors.

Palantir Exit He completely exited Palantir in early 2025. "There is explosive growth, but cheaper AI alternatives were preferred" was the explanation. Subsequent developments showed this exit was also debatable.

Healthcare-AI: The Real Big Bet Druckenmiller's strongest thesis: AI's best use case is in healthcare — drug discovery and diagnostics. And this sector has been under pressure for 4 years, meaning valuations make sense.

Five consecutive quarters of buying Teva Pharmaceuticals. Rationale: "rebirth story and AI synergy."

Hyperscaler Move Not playing hardware like Nvidia, but positions in Amazon, Alphabet, and Meta increased for infrastructure and monetization. Not completely exiting the AI opportunity, but entering cheaply within it.

Macro Warning "If the Fed cuts rates into a booming economy, inflation will reignite." Bearish view on the dollar maintained. Short position in bonds continues.